The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer.

This perspective describes the concurrent development in the 1980s of the first transgenic mice genetically engineered to express dominant oncogenes, involving independent researchers who were largely unaware of each other's strategies and progress. We relate the experimental designs, the pitfalls and challenges encountered, and the eventual success in developing distinctive mouse models of cancer, wherein tumors arose heritably in various organs. These early oncomice have produced a wealth of new knowledge, become topics of intellectual property, and spawned a vibrant field of cancer research that is revealing mechanisms of tumorigenesis and suggesting new therapeutic strategies for treating the human disease.

[1]  E. Wagner,et al.  Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene , 1988, Cell.

[2]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[3]  S. Lowe,et al.  p53-Dependent apoptosis suppresses tumor growth and progression in vivo , 1994, Cell.

[4]  D. Hanahan,et al.  T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Palmiter,et al.  Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice , 1987, Cell.

[6]  Masahiro Inoue,et al.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. , 2004, The Journal of clinical investigation.

[7]  R. Kerbel.  Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved , 2003, Cancer biology & therapy.

[8]  W. Alexander,et al.  Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice , 1991, Cell.

[9]  E. Wagner,et al.  Human beta-globin gene sequences injected into mouse eggs, retained in adults, and transmitted to progeny. , 1982, Science.

[10]  R. Hammer,et al.  Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice. , 1985, Cold Spring Harbor symposia on quantitative biology.

[11]  E. Wagner,et al.  AP-1 in mouse development and tumorigenesis , 2001, Oncogene.

[12]  S. Lowe,et al.  Genetic analysis of chemoresistance in primary murine lymphomas , 2000, Nature Medicine.

[13]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[14]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[15]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[16]  Chris Holman.  Clearing a Path through the Patent Thicket , 2006, Cell.

[17]  S. Lowe,et al.  INK 4 a / ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p 53 , 1999 .

[18]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[19]  Soyoung Lee,et al.  to the Outcome of Cancer Therapy , 2002 .

[20]  E. Wagner,et al.  The human beta-globin gene and a functional viral thymidine kinase gene in developing mice. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Hanahan,et al.  A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis , 1994, Nature.

[22]  R. Hammer,et al.  Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. , 1987, Science.

[23]  Christopher Chiu,et al.  Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis , 2006, Proceedings of the National Academy of Sciences.

[24]  M. Heller,et al.  Can Patents Deter Innovation? The Anticommons in Biomedical Research , 1998, Science.

[25]  Colleen V. Chien,et al.  Managing innovation: university-industry partnerships and the licensing of the Harvard mouse , 2004, Nature Biotechnology.

[26]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[27]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[28]  E. Wagner,et al.  c-fos expression induces bone tumors in transgenic mice. , 1989, Oncogene.

[29]  G. Hager,et al.  Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus , 1981, Cell.

[30]  D. Hanahan,et al.  Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells , 1987, Nature.

[31]  H. Symonds,et al.  Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[33]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Kathleen M. Smith,et al.  Pancreatic gene expression in rare cells of thymic medulla: evidence for functional contribution to T cell tolerance. , 1997, International immunology.

[35]  Ronald A. DePinho,et al.  Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.

[36]  J. Jonkers,et al.  Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects , 2006, Oncogene.

[37]  P. Leder,et al.  Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.

[38]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[39]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[40]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[41]  E. Wagner.  On transferring genes into stem cells and mice. , 1990 .

[42]  R. Palmiter,et al.  SV40 enhancer and large-T antigen are instrumental in development of choroid plexus tumours in transgenic mice , 1985, Nature.

[43]  R. Jaenisch,et al.  Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Hanahan,et al.  Bovine papillomavirus genome elicits skin tumours in transgenic mice , 1986, Nature.

[45]  D. Troyer,et al.  Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. , 2002, Cancer research.

[46]  A. W. Harris,et al.  The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice , 1986, Cell.

[47]  E. Wagner,et al.  c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. , 1995, Cancer research.

[48]  N. Heerema,et al.  Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. , 2007, Cancer research.

[49]  R. Palmiter,et al.  Differential regulation of metallothionein-thymidine kinase fusion genes in transgenic mice and their offspring , 1982, Cell.

[50]  Erwin F. Wagner,et al.  Deregulated c-fos expression interferes with normal bone development in transgenic mice , 1987, Nature.

[51]  R. Palmiter,et al.  Metallothionein-human GH fusion genes stimulate growth of mice. , 1983, Science.

[52]  Michael G. Rosenfeld,et al.  Dramatic growth of mice that develop from eggs microinjected with metallothionein–growth hormone fusion genes , 1982, Nature.

[53]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[54]  D. Hanahan,et al.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. , 2004, Cancer cell.

[55]  Craig Freeman,et al.  A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer , 2005, Oncogene.

[56]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[57]  E. Marshall.  DuPont Ups Ante on Use of Harvard's OncoMouse , 2002, Science.

[58]  Gerhard Christofori,et al.  A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.

[59]  A. Strasser,et al.  Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. , 2007, Blood.

[60]  J. Pipas,et al.  T-antigen mutant activities in vivo: roles of p53 and pRB binding in tumorigenesis of the choroid plexus. , 1992, Oncogene.

[61]  F. Costantini,et al.  Introduction of a rabbit β-globin gene into the mouse germ line , 1981, Nature.

[62]  D. Hanahan,et al.  Endothelial cell tumors develop in transgenic mice carrying polyoma virus middle T oncogene , 1987, Cell.

[63]  R. Palmiter,et al.  Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs , 1981, Cell.

[64]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[65]  D. Hanahan,et al.  Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development. , 1992, Genes & development.

[66]  Germ-line transformation of mice. , 1986, Annual review of genetics.

[67]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[68]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[69]  R. Palmiter,et al.  Transgenic mice harboring SV40 t-antigen genes develop characteristic brain tumors , 1984, Cell.

[70]  D. Troyer,et al.  Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors , 2000, Oncogene.

[71]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[72]  P. Leder,et al.  Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development , 1986, Cell.

[73]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[74]  Patrick J. Paddison,et al.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.

[75]  F H Ruddle,et al.  Genetic transformation of mouse embryos by microinjection of purified DNA. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[76]  E. Wagner,et al.  Essential role of RSK2 in c-Fos-dependent osteosarcoma development. , 2005, The Journal of clinical investigation.

[77]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[78]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[79]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.